Rochester, NY 6/11/2009 2:17:36 PM
WFWS "After Market Most Active by Volume -Nasdaq" - Microsoft Corporation,MSFT - Amgen Inc.,AMGN - Sequenom, Inc.,SQNM
Microsoft Corporation - Amgen Inc. - Sequenom, Inc.
WFWS "After Market Most Active by Volume -Nasdaq" - Microsoft Corporation,MSFT - Amgen Inc.,AMGN - Sequenom, Inc.,SQNM
Microsoft Corporation,MSFT
After Hours: 22.25 Down 0.30 (1.33%) 8:01PM ET
Last Trade: 22.55
Day's Range: 22.12 - 22.62
52wk Range: 14.87 - 29.57
Volume: 61,297,117
REDMOND, Wash. and WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- As organizations of all shapes and sizes are making every possible effort to deliver greater value to their business and customers, IT managers are being required to increase the efficiency of their operational infrastructure, systems and processes. As a result, a greater number of companies are signing on for the interoperability and intellectual property (IP) peace of mind solutions offered by Novell Inc. and Microsoft Corp. through their business, legal and technical collaboration agreement.
ABOUT
Microsoft Corporation provides software products for computing devices worldwide. Its Client segment offers Windows product family that comprises Windows Vista; Windows XP Professional and Home; Media Center Edition; Tablet PC Edition; and other Windows operating systems. The companys Server and Tools segment provides integrated server infrastructure and middleware software that support software applications and tools built on the Windows Server operating system. This segment offers Windows Server operating system; Microsoft SQL Server; Microsoft Enterprise Services; product support services; Visual Studio; System Center products; Forefront Security products; Biz Talk Server; and MSDN. Its Online Services Business provides an on-line advertising platform for publishers and advertisers; personal communications services, such as email and instant messaging; and online information.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In todayís market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Amgen Inc.,AMGN
After Hours: 50.85 Up 0.74 (1.48%) 8:01PM ET
Last Trade: 50.11
Day's Range: 49.60 - 51.94
52wk Range: 42.90 - 66.51
Volume: 9,289,273
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada. The company was founded in 1980 and is based in Thousand Oaks, California.
---
Sequenom, Inc.,SQNM
After Hours: 4.05 Down 0.04 (0.98%) 7:59PM ET
Last Trade: 4.09
Day's Range: 4.07 - 5.06
52wk Range: 2.86 - 29.14
Volume: 53,585,410
Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. Sequenom also provides the iPLEX multiplexing assay reagents and chips, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. In addition, the company engages in the research, development, and the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, and infectious diseases.
---
Do not invest in these stocks because we mentioned them in this release. We never include our picks in these news releases. This is just to alert you to our service. Our alerts are saved for our subscribers. To receive Alerts on the stock we feel are going to move, sign up for our free alert service.
Visit WhisperfromWallStreet.com to sign up for your FREE subscription or download our free Windows Vista or iGoogle gadget for instant alerts direct to your desktop or iGoogle page.
If you are a public company looking to generate investor awareness for your company please contact us at info@WhisperfromWallStreet.com.
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com 585-301-7700
